A preclinical study of an AML-xenograft mouse model showed that cytokine production and proliferation of FLT3-targeted CAR-T cells were strongly increased by FLT3 upregulation (4- to 13-fold) in leukemic cells after exposure to FLT3 inhibitors, which resulted in a 100% response rate when combined with FLT3-targeted CAR-T and FLT3 inhibitors [113]. The gene discussed is FLT3; the disease is acute myeloid leukemia.